ALDH18A1 and telomere syndrome: Finally, we investigated whether the GPR-TME signatures could predict the response to immunotherapy in patients with STS, and the response to immunotherapy differed among risk groups in this model, with lower GPR signatures or higher TME signatures implying better levels of immune response.